Renaissance Capital logo


Renaissance Capital's November IPO Market Update


Eleven US IPOs raised a combined $708 million in November, well below the month's historical 10-year average (16 IPOs, $4.2B). Deal flow was led by three sizable issuers, and remaining activity came from smaller companies, all of which raised $33 million or less. The month's IPOs averaged a weak -22% return from offer, and only two deals finished above issue, both of which more

CAR T cancer biotech CARGO Therapeutics targets a $300 million IPO, as it seeks to overcome weak trading from recent biotech listings


Another large biotech IPO has joined the calendar, seeking to buck the trend of mostly negative returns from recent listings in the industry. CARGO Therapeutics (CRGX) launched on Monday, planning to raise $300 million in what would be the year's fourth-largest biotech IPO to date. Its proposed deal size would put it in the largest 5% of biotech IPOs in the more

US IPO Weekly Recap: Biotech Lexeo stumbles after $100 million IPO


After ending October on shaky footing, the IPO market kicked off November with a fairly quiet week. Three new issuers began trading, two of which qualified for inclusion in our stats, while one deal was pushed back (SHIM). Four small Asia-based companies more

Gene therapy biotech Lexeo Therapeutics prices IPO at $11, below the range


Lexeo Therapeutics, a Phase 1 biotech developing gene therapies for cardio and neuro diseases, raised $100 million by offering 9.1 million shares at $11, below the range of $13 to $15. The company offered 91 thousand more shares than anticipated. Lexeo Therapeutics is a genetic medicine company focused on fundamentally changing how disease is treated by pioneering science. more